Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7279483 | Brain, Behavior, and Immunity | 2018 | 45 Pages |
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques, neurofibrillary tangles, and neuronal loss, accompanied by neuroinflammation. Neuroinflammatory processes are thought to contribute to AD pathophysiology. Metformin has been reported to have anti-inflammatory efficacy. However, whether metformin is responsible for the anti-neuroinflammation and neuroprotection on APPswe/PS1ÎE9 (APP/PS1) mice remains unclear. Here we showed that metformin attenuated spatial memory deficit, neuron loss in the hippocampus and enhanced neurogenesis in APP/PS1 mice. In addition, metformin administration decreased amyloid-β (Aβ) plaque load and chronic inflammation (activated microglia and astrocytes as well as pro-inflammatory mediators) in the hippocampus and cortex. Further study demonstrated that treatment with metformin enhanced cerebral AMPK activation. Meanwhile, metformin notably suppressed the activation of P65 NF-κB, mTOR and S6K, reduced Bace1 protein expression. Our data suggest that metformin can exert functional recovery of memory deficits and neuroprotective effect on APP/PS1 mice via triggering neurogenesis and anti-inflammation mediated by regulating AMPK/mTOR/S6K/Bace1 and AMPK/P65 NF-κB signaling pathways in the hippocampus, which may contribute to improvement in neurological deficits.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Zhenri Ou, Xuejian Kong, Xiangdong Sun, Xiaosong He, Le Zhang, Zhuo Gong, Jingyi Huang, Biao Xu, Dahong Long, Jianhua Li, Qingqing Li, Liping Xu, Aiguo Xuan,